

DEC. 16. 2004 11:13AM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 0669 P. 1

DEC 16 2004

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)


TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/721,210	
	Filing Date	November 25, 2003	
	First Named Inventor	Hervé BOUCHARD et al.	
	Art Unit	1625	
	Examiner Name	Davis, Zinna Northington	
Total Number of Pages in This Submission	17 pgs.	Attorney Docket Number	ST01018G1 US CNT

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	<div style="border: 1px solid black; padding: 5px;"> 1. Response to Restriction/Election Requirement Under 35 U.S.C. § 121 (4 pgs.) </div>
Remarks			
1. Copy of IPER of PCT/FR02/01767 (6 pgs.)			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Balaram Gupta		
Date	December 16, 2004	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. (703) 872-9306 ; Total No. of Pages Transmitted: 7 pgs.)

Signature	
Typed or printed name	Maribel Mendez
Date	December 16, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
CENTRAL FAX CENTER

PATENT

Docket No.: ST01018G1-US-CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Herve Bouchard

Serial No.: **10/721,210**

Filed: **November 25, 2003**

Title: **Chemical Derivatives and Their
Application as Antitelomerase Agent**

Examiner: **Davis, Zinna Northington**

Art Unit: **1625**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile at 703-372-9306 to the Commissioner for Patents, Washington, D.C. 20231, on

December 16, 2004

Maibel Mende
Signature

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Restriction/Election Requirement Under 35 U.S.C. § 121

Sir:

This is in response to the Office Action, dated, November 16, 2004, having a response due by, December 16, 2004 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

PROVISIONAL ELECTION OF A PREFERRED SPECIES:

Applicants provisionally elect with traverse a preferred specie of the compound of claim 1 wherein n, m, p, q are 1, nitrogen containing aromatic ring is a quinoline optionally substituted as recited in claim 1, the aromatic or non-aromatic ring is a quinoline optionally substituted as recited in claim 1, R₃ and R_{3'} are hydrogen or C₁₋₄ alkyl, and the distribution agent is a 5- or 6-membered heterocyclic radical. A compound falling within the scope of the elected specie is bis[(4-dimethylamino-2-methylquinolin-